Impact of elexacaftor/tezacaftor/ivacaftor combination therapy on lung function in adults with cystic fibrosis: Beyond FEV1
M. Wollsching-Strobel (Cologne, Germany), D. Dieninghoff (Cologne, Germany), L. Emrich (Cologne, Germany), D. Kroppen (Cologne, Germany), D. Majorski (Cologne, Germany), T. Mathes (Goettingen, Germany), F. Magnet (Cologne, Germany), S. Schwarz (Cologne, Germany), C. Crieé (Goettingen, Germany), W. Windisch (Cologne, Germany)
Source: International Congress 2022 – Physiologic studies of respiratory diseases
Session: Physiologic studies of respiratory diseases
Session type: Thematic Poster
Number: 2758
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Wollsching-Strobel (Cologne, Germany), D. Dieninghoff (Cologne, Germany), L. Emrich (Cologne, Germany), D. Kroppen (Cologne, Germany), D. Majorski (Cologne, Germany), T. Mathes (Goettingen, Germany), F. Magnet (Cologne, Germany), S. Schwarz (Cologne, Germany), C. Crieé (Goettingen, Germany), W. Windisch (Cologne, Germany). Impact of elexacaftor/tezacaftor/ivacaftor combination therapy on lung function in adults with cystic fibrosis: Beyond FEV1. 2758
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|